Transitioning to Cost-Effective Praesto™ AP+ Resins: Streamlining mAb Purification

As global healthcare systems push for affordability, reducing the cost of monoclonal antibody (mAb) manufacturing has become a top priority. Chromatographic capture and polishing steps remain among the most expensive operations in downstream processing, especially in legacy workflows. Moving to modern resins can deliver significant savings and productivity gains, but the transition must preserve product quality, regulatory compliance, and compatibility with existing processes.

This presentation examines the challenges and opportunities in replacing traditional Protein A resins with next-generation alternatives. We will explore why cost pressures and biosimilar development are driving change, outline critical considerations for resin adoption, and share strategies to minimize complexity during implementation. Finally, we will highlight how Ecolab’s Praesto AP+ Resin Platform was engineered to simplify this transition, offering robust performance, regulatory assurance, and cost efficiency for commercial and biosimilar manufacturing. Attendees will gain practical insights into planning and executing resin transitions that deliver measurable benefits without disrupting established workflows.